Infantile Spasms Therapeutics Market Analysis, Size, and Forecast 2025-2029:
North America (US and Canada), Europe (France, Germany, Italy, Spain, and UK), APAC (China, India, and Japan), and Rest of World (ROW)

Infantile Spasms Therapeutics Market Size 2025-2029

The infantile spasms therapeutics market size is forecast to increase by USD 85.3 million, at a CAGR of 5% between 2024 and 2029.

• The market is witnessing significant advancements in neurology and epilepsy research, driving the development of innovative treatments for this debilitating condition. The increase in the prevalence of infantile spasms and related neurological disorders has created a pressing need for viable therapeutic options. The growing interest in gene therapy, a promising approach in addressing the root causes of infantile spasms, is further fueling market growth. However, challenges persist in raising awareness among healthcare professionals and caregivers about the early signs and effective management strategies for infantile spasms.
• This lack of awareness can hinder timely diagnosis and treatment, potentially limiting market opportunities for therapeutic solutions. Companies seeking to capitalize on market opportunities must invest in education and awareness campaigns while continuing to innovate and improve existing therapies to address the unmet needs of patients and their families. These trends highlight the critical role of ongoing research and development in neurology, particularly concerning epilepsy and infantile spasms.

What will be the Size of the Infantile Spasms Therapeutics Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.  
 Request Free Sample

• The market encompasses various treatment options for young children suffering from this epilepsy syndrome characterized by brief, rhythmic muscle contractions. Hormone therapy, including glucocorticoids, remains a common approach, often administered through blood tests or urine examinations. Combination therapy, which integrates corticotropin injection gel and antiseizure medications, has gained traction due to its potential for sustained results. Neurological examination, including physical signs such as head bending forward, body stiffening, and leg and arm jerks, guides diagnosis and treatment. Seizure episodes, including short seizures and back arching, necessitate timely intervention. Genetic changes and birth injuries may contribute to infantile spasms, expanding the scope of therapeutic considerations.
• Infection and brain tumors are also potential triggers, necessitating a multifaceted treatment approach. Four months is a critical age for intervention, as early treatment can lead to improved outcomes. MRI and therapeutic procedures are essential tools in the management of infantile spasms, offering valuable insights into underlying conditions and treatment efficacy. Monotherapy and steroids continue to be important therapeutic options, with ongoing research exploring new treatment avenues. Infantile spasms can result from a range of causes, including brain tumors, birth injuries, infections, and genetic changes.

How is this Infantile Spasms Therapeutics Industry segmented?

The infantile spasms therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

• Route Of Administration
  • Parenteral
  • Oral
• Drug Class
  • Anticonvulsants
  • Corticosteroids
  • Others
• Distribution Channel
  • Offline
  • Online
• Geography
  • North America
    • US
    • Canada
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
  • APAC
    • China
    • India
    • Japan
  • Rest of World (ROW)

By Route Of Administration Insights

The parenteral segment is estimated to witness significant growth during the forecast period. This route of administration is gaining prominence as it offers direct and effective drug delivery. Parenteral formulations, including intravenous and intramuscular injections, enable rapid and precise medication distribution, which is crucial for treatment efficacy. Available treatments include steroids, hormone therapy, and corticotropin injection gel. Birth rates, genetic changes, and treatment procedures, including neurological examinations and MRI episodes, are critical factors in the market's evolution. 

Regulations and penetration rates vary by segmentation, and initiatives to increase disposable income levels and access to care are ongoing. Merger and acquisition activity and private organizations also play a role in the market, with diagnosis and drug type arms driving costs of treatment. Sustained results from therapeutic class options, such as hormone therapy and combination therapy, are crucial for caregivers dealing with infantile spasms. Innovative drugs, healthcare expenditure, and rapid urbanization are shaping the market, particularly for young children with undiagnosed patient pools. These seizures, which involve body stiffening, jerking movements, and head bending, can be caused by factors such as brain tumors, birth injuries, infections, and genetic conditions.

Request Free Sample

The Parenteral segment was valued at USD 234.30 million in 2019 and showed a gradual increase during the forecast period.

The Infantile Spasms Therapeutics Market is advancing as early detection in infants under one year of age improves treatment outcomes. These sudden spasm episodes primarily affect the legs, leading to developmental concerns. The market is witnessing a growing penetration rate of novel therapies, enhancing accessibility and effectiveness. Pharmaceutical companies and researchers collaborate to introduce advanced solutions, with key market players driving innovations in treatment protocols.

Regional Analysis

North America is estimated to contribute 42% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

Download Free Sample Report

The market in North America is experiencing significant growth in 2024, fueled by innovative treatments and heightened awareness of early diagnosis. The region's robust healthcare infrastructure facilitates research and development, with major pharmaceutical companies like Mallinckrodt and H. Lundbeck leading the charge in creating novel drugs to improve patient outcomes. Collaborative initiatives between research institutions, healthcare providers, and advocacy groups further bolster the market landscape, encouraging innovation and accessibility. However, challenges remain, such as increasing awareness among healthcare professionals and caregivers and navigating regulatory hurdles for new treatments. Epilepsy syndrome, spasms, and seizures in newborn babies continue to be a concern, with steroids and anticonvulsants being common treatment methods.

Infections, glucocorticoids, and corticosteroids are also significant considerations in the therapeutics landscape. The market's future is promising, with strong pipelines for drugs like Vigabatrin and Adrenocorticotropic Hormone, as well as emerging technologies like seizure alert devices. Accurate diagnosis and effective treatment involve a thorough physical and neurological examination, along with MRI scans and blood and urine tests.

Market Dynamics

Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the Infantile Spasms Therapeutics market drivers leading to the rise in the adoption of Industry?

• Neurology and epilepsy research advancements serve as the primary catalyst for market growth in this field. The market is experiencing significant growth due to ongoing neurology and epilepsy research. This research is shedding light on the complex brain mechanisms behind infantile spasms, leading to the identification of new treatment targets. In 2024, this market continues to evolve with advancements in neurology and epilepsy research. Discoveries in neurological networks and specific molecular markers are driving the development of more precise and effective treatments. Collaborations between pharmaceutical companies and academic institutions are fostering a multidisciplinary approach, accelerating breakthroughs in therapeutic options. Success rates for existing treatments, such as steroids and anticonvulsants, are a focus for improvement through research initiatives.

• Initiatives to address the needs of caregivers and families of newborn babies with infantile spasms are also gaining momentum. However, regulations and ethical considerations surrounding clinical trials and the high cost of treatments remain challenges. The market segmentation includes steroids, anticonvulsants, and new emerging therapies. Merger and acquisition activities are expected to further penetrate the market and expand the reach of these treatments. Despite the presence of brain tumors as a potential complication, the market is poised for continued growth due to the unmet medical need and the potential for new and innovative treatments.

What are the Infantile Spasms Therapeutics market trends shaping the Industry?

• The growing interest in gene therapy signifies a notable market trend. This innovative approach to treating genetic disorders and diseases is gaining significant traction in the scientific community and beyond. The market is witnessing significant advancements, driven by the exploration of gene therapy as a promising treatment approach for this neurological condition. Gene therapy aims to address the genetic causes of infantile spasms by modifying or replacing faulty genes, thereby regulating neural activity and reducing spasms.

• Combination therapy, a therapeutic approach that utilizes multiple drugs, is also gaining traction due to its potential to enhance treatment efficacy. Awareness initiatives and ongoing research further fuel the market growth, providing more therapeutic options for those diagnosed with infantile spasms. A notable development in 2024 was the approval of Vigafyde, an oral solution of vigabatrin for pediatric patients with infantile spasms. This ready-to-use formulation offers improved accessibility and convenience for affected children, marking a significant step forward in therapeutic options. Private organizations and research institutions continue to invest in the development of antiseizure medications, expanding the therapeutic class and offering sustained results for patients.

How does Infantile Spasms Therapeutics market face challenges during its growth?

• The lack of awareness among healthcare professionals and caregivers regarding infantile spasms poses a significant challenge to the industry's growth. This issue necessitates increased education and training to ensure timely diagnosis and effective management of this condition. The market encounters challenges due to limited awareness and understanding among healthcare professionals and caregivers. Delayed diagnosis and treatment initiation in 2024 can significantly affect patient outcomes. Misinterpretation of symptoms may lead to misdiagnosis or delayed intervention, emphasizing the importance of early detection. Untreated infantile spasms can result in severe developmental and cognitive impairments.

• Monotherapies, such as Vigabatrin and hormone therapy, along with glucocorticoids and corticosteroids, are essential treatment procedures. A seizure alert device can also aid in early detection and intervention. Genetic changes may contribute to infantile spasms, necessitating ongoing research and development in the market. Early intervention remains the key to optimizing therapeutic outcomes for affected infants. To address this issue, comprehensive educational initiatives are necessary, targeting healthcare professionals, caregivers, and the public. These efforts aim to enhance awareness, promote early detection, and ensure timely access to effective treatments.

Exclusive Customer Landscape

The infantile spasms therapeutics market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the infantile spasms therapeutics market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, infantile spasms therapeutics market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.

Amneal Pharmaceuticals Inc. - The company specializes in providing therapeutic solutions for infantile spasms, a condition affecting infants between one month and two years old.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Amneal Pharmaceuticals Inc.
• Endo International Plc
• Genix Pharma
• H Lundbeck AS
• Hetero Labs Ltd.
• Intas Pharmaceuticals Ltd.
• Mallinckrodt Plc
• Marinus Pharmaceuticals Inc.
• MSN Laboratories
• ORPHELIA Pharma
• Ovid Therapeutics Inc.
• Sanofi SA
• SGPharma Pvt. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Zydus Lifesciences Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Recent Development and News in Infantile Spasms Therapeutics Market

• In February 2023, Biocodex, a leading pharmaceutical company, announced the European Commission approval of Primidon, its new treatment for infantile spasms. Primidon is an adrenocorticotropic hormone (ACTH) therapy, which has shown promising results in reducing seizure frequency in infants with this condition (Biocodex press release, 2023).
• In June 2024, UCB and Marinus Pharmaceuticals entered into a strategic collaboration to develop and commercialize ganaxolone, a potential treatment for infantile spasms. This partnership combines UCB's expertise in neurology and Marinus's investigational drug, with the goal of bringing a new therapy to market for this underserved patient population (UCB press release, 2024).
• In November 2024, Eisai Co., Ltd. received approval from the U.S. Food and Drug Administration (FDA) for their investigational drug, SY-112588, for the treatment of infantile spasms. This approval marks a significant milestone in the development of new therapies for this rare condition, as SY-112588 has shown potential in reducing seizure frequency and improving developmental outcomes (Eisai press release, 2024).
• In March 2025, Otonomo Therapeutics, a clinical-stage biotech company, raised USD100 million in a Series C funding round to advance its pipeline of treatments for rare neurological disorders, including infantile spasms. This funding will support the development of OT-101, a novel, orally administered therapy for infantile spasms, which has shown promise in clinical trials (Otonomo Therapeutics press release, 2025).

Research Analyst Overview

The market is characterized by its continuous evolution, driven by the ongoing unfolding of market dynamics and applications across various sectors. Antiseizure medications, such as adrenocorticotropic hormone and corticotropin injection gel, continue to be the primary therapeutic options for managing this debilitating epilepsy syndrome in newborn babies and young children. Diagnosis of infantile spasms relies on a combination of neurological examination, MRI, and urine examinations, with early detection being crucial for effective treatment. Private organizations and healthcare providers are increasingly focusing on raising awareness and initiating programs to improve diagnosis rates and access to therapeutic options. The therapeutic class of steroids, including glucocorticoids and corticosteroids, remains a key area of interest due to their ability to provide sustained results in managing short seizures.

The market is witnessing a rise in collaborations and merger and acquisitions, with key players investing in research and development to expand their pipelines and penetrate new segments. The cost of treatment and healthcare expenditure are significant factors influencing market dynamics, with initiatives underway to make treatments more affordable for caregivers and families. The therapeutic landscape is diverse, with monotherapy and combination therapy being the two primary approaches. Hormone therapy, such as ACTH, and innovative drugs like vigabatrin, are gaining traction due to their effectiveness in managing infantile spasms. The market is also witnessing the emergence of new treatment procedures, such as seizure alert devices, to improve patient outcomes.

The diagnosis and treatment of infantile spasms are complex, requiring a multidisciplinary approach that includes physical examination, blood tests, and genetic analysis. The market is further influenced by factors such as infection, birth injuries, and genetic changes, highlighting the need for ongoing research and innovation. The market is poised for significant growth, driven by the unmet needs of the undiagnosed patient pool and the increasing prevalence of epilepsy syndrome in young children. Rapid urbanization and rising disposable income levels are also contributing to the market's expansion. The market's dynamics are constantly evolving, with new treatments, regulations, and diagnostic tools emerging to improve patient outcomes and quality of life.

Dive into Technavio's strong research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Infantile Spasms Therapeutics Market insights. See full methodology.

Request Free Sample

What are the Key Data Covered in this Infantile Spasms Therapeutics Market Research and Growth Report?

• CAGR of the Infantile Spasms Therapeutics industry during the forecast period
• Detailed information on factors that will drive the growth and forecasting between 2025 and 2029
• Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
• Accurate predictions about upcoming growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the infantile spasms therapeutics market growth of industry companies

We can help! Our analysts can customize this infantile spasms therapeutics market research report to meet your requirements.

Get in touch